{
    "nct_id": "NCT03689712",
    "official_title": "ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer",
    "inclusion_criteria": "* squamous cell carcinoma of the head and neck\n* treatment plan to receive IMRT delivered as single daily fractions of 2.0 to 2.2 Gy with a cumulative radiation dose of 60-72 Gy\n* Treatment plan to receive standard cisplatin monotherapy\n* Age 18 years or older\n* Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 2\n* Adequate hematologic, renal and liver function\n* Negative serum pregnancy test\n* Use of effective contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Tumor of the lips, larynx, hypopharynx, nasopharynx, sinuses, or salivary glands\n* Metastatic disease\n* Prior radiotherapy to the region of the study cancer or adjacent anatomical\n* Prior induction chemotherapy\n* Receiving any approved or investigational anti-cancer agent other than those provided for in this study\n* Concurrent participation in another interventional clinical study\n* Inability to eat soft solid food at baseline\n* Malignant tumors other than HNC within the last 5 years\n* Active infectious disease excluding oral candidiasis\n* Presence of oral mucositis at baseline\n* Known history of HIV or active hepatitis B/C\n* Female patients who are pregnant or breastfeeding\n* Known allergies or intolerance to cisplatin and similar platinum-containing compounds\n* Requirement for concurrent treatment with nitrates or other drugs that may create a risk for a precipitous decrease in blood pressure",
    "miscellaneous_criteria": ""
}